careers & recruitment

People Recent moves of note in and around the biotech and pharma industries.

over 20 years of experience in the pharma Clinical-stage biopharma Humanigen has announced the industry, including significant gene therapy appointment of Adrian Kilcoyne (photo) to the newly created translational and development expertise. role of chief medical officer. He brings leadership experience Reape was most recently chief medical from multinational pharma and biotech companies and a officer at Spark Therapeutics. strong clinical background in internal medicine and medicine, having recently served as of Clinical-stage precision medicine oncology global medical affairs, head of evidence generation company Relay Therapeutics has named and external alliances at AstraZeneca. Patrick Riley senior vice president of “Dr. Kilcoyne’s experience and knowledge in multiple areas, including COVID-19, artificial intelligence. Riley has over a CAR-T and other oncology clinical development areas, medical affairs, regulatory affairs, decade of data science and machine learning evidence generation, and partnering, gives him a unique insight that can experience from Google, initially in web be leveraged towards Humanigen’s COVID-19, acute GvHD, CAR-T and other oncology search and user behavior analysis and programs with lenzilumab and ifabotuzumab,” said Humanigen CEO Cameron Durrant. later as a principal engineer and senior “In addition, Adrian’s leadership in the external alliances arena will be instrumental in researcher on the Google Accelerated helping guide the progress of Humanigen’s pipeline and potential commercialization.” Science team. In addition, Relay has appointed Charles Ferté, formerly AstraZeneca’s senior director and global project leader of oncology R&D, as its Laura Carter has been appointed CSO of Precision metagenomics company vice president and lead for RLY-4008, a Gossamer Bio, succeeding Luisa Salter-Cid. IDbyDNA has named Neil Gunn CEO. small-molecule inhibitor of FGFR2—a Carter joined Gossamer in 2019 as senior Gunn joins the company after 12 years receptor tyrosine kinase that is frequently vice president of research and translational at Roche Diagnostics, where he was altered in certain cancers—and Tara biology after leading the development most recently president and head of O’Meara, formerly head of bluebird of immunology and immuno-oncology Roche Sequencing. bio’s clinical development operations, programs at Lycera. as senior vice president of clinical Carmine Therapeutics has appointed development operations. Candel Therapeutics has named Carrie S. Don Haut CEO and a member of the Cox chairman of the . board of directors. Haut brings more than Clinical-stage biotech CohBar has named Cox is currently the chairman of Organon two decades of healthcare experience to Joseph J. Sarret CEO and a member of the and was previously chairman at Array Carmine, having previously served as board of directors, succeeding Steven Engle. Biopharma and a director on the board at AskBio and Sarret most recently served as chief business of Celgene. Before her board roles, she Sherlock Biosciences. officer at Corium International and was served as executive vice president and previously senior vice president, strategic president of Schering-Plough’s global Tom Klima has joined bluebird bio as accounts at Solazyme. pharmaceutical business. . He was most recently at Gamida Cell, where he served in LianBio has announced the appointment of Quantum-Si, which is pioneering the same capacity. Yizhe Wang as CEO and a member of the next-generation semiconductor chip-based board of directors. He joins LianBio from proteomics, has named Marijn Dekkers Jaguar Gene Therapy has named Joe Eli Lilly, where he most recently served as and Ruth Fattori to its board of directors. McIntosh chief medical officer. He joins global brand development leader for Lilly’s Dekkers was the founder and chairman of the company from Aruvant, a Roivant oncology business. Previously, he was senior Novalis LifeSciences and formerly CEO of subsidiary, where he led development of a vice president, head of biomedicines and Bayer AG and Thermo Fisher Scientific. gene therapy for sickle cell disease as the oncology businesses for Lilly China. Fattori was managing partner of Pecksland company’s chief medical officer. Previously, Partners and formerly executive vice he served as head of clinical development Centessa Pharmaceuticals has announced president and chief human resources at PTC Therapeutics. the appointment of Antoine Yver as chief officer of PepsiCo. medical officer. Yver brings over 30 years of Former president of Merck Research global experience in the pharma industry. Acepodia has appointed Thorsten Graef Laboratories Roger Perlmutter has joined He joins the company from Daiichi Sankyo, chief medical officer and Michael Brock Eikon Therapeutics as CEO. Perlmutter where he served as executive vice president . Graef most recently spent eight years as head of Merck’s and global head, R&D oncology, and chair of served as vice president of oncology early R&D group before stepping down at the the cancer enterprise. development at AbbVie, and Brock joins end of last year. the company from Wells Fargo Securities, where he was a managing director in the Kathy Reape has been appointed chief Published online: 10 June 2021 healthcare investment banking group. development officer at Akouos. She brings https://doi.org/10.1038/s41587-021-00956-x

780 Nature Biotechnology | VOL 39 | June 2021 | 776–780 | www.nature.com/naturebiotechnology